ALLR vs. AFMD, BFRG, CARM, EVAX, FNCH, BTAI, SYBX, GLYC, BCTX, and NNVC
Should you be buying Allarity Therapeutics stock or one of its competitors? The main competitors of Allarity Therapeutics include Affimed (AFMD), Bullfrog AI (BFRG), Carisma Therapeutics (CARM), Evaxion Biotech A/S (EVAX), Finch Therapeutics Group (FNCH), BioXcel Therapeutics (BTAI), Synlogic (SYBX), GlycoMimetics (GLYC), BriaCell Therapeutics (BCTX), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical products" industry.
Allarity Therapeutics vs.
Allarity Therapeutics (NASDAQ:ALLR) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, community ranking, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.
In the previous week, Allarity Therapeutics had 1 more articles in the media than Affimed. MarketBeat recorded 1 mentions for Allarity Therapeutics and 0 mentions for Affimed. Affimed's average media sentiment score of 1.00 beat Allarity Therapeutics' score of 0.16 indicating that Affimed is being referred to more favorably in the news media.
Affimed received 438 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. Likewise, 70.24% of users gave Affimed an outperform vote while only 50.00% of users gave Allarity Therapeutics an outperform vote.
11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 30.8% of Affimed shares are held by institutional investors. 0.0% of Allarity Therapeutics shares are held by insiders. Comparatively, 3.8% of Affimed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Allarity Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, Affimed has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500.
Affimed has a consensus price target of $13.50, indicating a potential upside of 1,084.21%. Given Affimed's stronger consensus rating and higher possible upside, analysts clearly believe Affimed is more favorable than Allarity Therapeutics.
Allarity Therapeutics has higher earnings, but lower revenue than Affimed.
Allarity Therapeutics has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Affimed's return on equity of -193.84% beat Allarity Therapeutics' return on equity.
Summary
Affimed beats Allarity Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Allarity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allarity Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALLR) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ALLR Stock Alerts